Longevity Biomedical (Longevity Biomedical) Sloan Ratio % : 0.00% (As of . 20)

Longevity Biomedical Sloan Ratio % Chart

Competitive Comparison of Longevity Biomedical's Sloan Ratio %

For the Biotechnology subindustry, Longevity Biomedical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Sloan Ratio % falls into.

Longevity Biomedical Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Longevity Biomedical's Sloan Ratio for the fiscal year that ended in . 20 is calculated as

Longevity Biomedical's Sloan Ratio for the quarter that ended in . 20 is calculated as

Longevity Biomedical does not have enough years/quarters to calculate the Net Income, Cash Flow from Investing, and Cash Flow from Investing for the trailing twelve months (TTM) ended in . 20.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical  (NAS:LBIO) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of . 20, Longevity Biomedical has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

Longevity Biomedical Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Longevity Biomedical (Longevity Biomedical) Business Description